JP2025020119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025020119A5 JP2025020119A5 JP2024174007A JP2024174007A JP2025020119A5 JP 2025020119 A5 JP2025020119 A5 JP 2025020119A5 JP 2024174007 A JP2024174007 A JP 2024174007A JP 2024174007 A JP2024174007 A JP 2024174007A JP 2025020119 A5 JP2025020119 A5 JP 2025020119A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- administered
- composition according
- hodgkin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344880P | 2016-06-02 | 2016-06-02 | |
| US62/344,880 | 2016-06-02 | ||
| PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
| JP2018563008A JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2022178836A JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178836A Division JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025020119A JP2025020119A (ja) | 2025-02-12 |
| JP2025020119A5 true JP2025020119A5 (https=) | 2025-06-23 |
Family
ID=59067911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563008A Active JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2022178836A Active JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2024174007A Pending JP2025020119A (ja) | 2016-06-02 | 2024-10-03 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563008A Active JP7175198B2 (ja) | 2016-06-02 | 2017-06-01 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| JP2022178836A Active JP7568698B2 (ja) | 2016-06-02 | 2022-11-08 | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11083790B2 (https=) |
| EP (2) | EP4248990A3 (https=) |
| JP (3) | JP7175198B2 (https=) |
| KR (2) | KR20230038318A (https=) |
| CN (1) | CN109475633A (https=) |
| DK (1) | DK3463457T3 (https=) |
| ES (1) | ES2954139T3 (https=) |
| FI (1) | FI3463457T3 (https=) |
| HR (1) | HRP20230864T1 (https=) |
| HU (1) | HUE062398T2 (https=) |
| LT (1) | LT3463457T (https=) |
| PL (1) | PL3463457T3 (https=) |
| PT (1) | PT3463457T (https=) |
| RS (1) | RS64388B1 (https=) |
| SI (1) | SI3463457T1 (https=) |
| SM (1) | SMT202300290T1 (https=) |
| WO (1) | WO2017210453A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| US11299543B2 (en) | 2016-06-02 | 2022-04-12 | Bristol-Myers Squibb Company | Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment |
| LT3463457T (lt) | 2016-06-02 | 2023-09-11 | Bristol-Myers Squibb Company | Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą |
| WO2019140150A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| LT3463457T (lt) | 2016-06-02 | 2023-09-11 | Bristol-Myers Squibb Company | Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą |
-
2017
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Ceased
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en not_active Ceased
- 2017-06-01 SM SM20230290T patent/SMT202300290T1/it unknown
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko not_active Ceased
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en not_active Abandoned
-
2022
- 2022-11-08 JP JP2022178836A patent/JP7568698B2/ja active Active
-
2024
- 2024-10-02 US US18/905,043 patent/US20250134996A1/en active Pending
- 2024-10-03 JP JP2024174007A patent/JP2025020119A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020119A5 (https=) | ||
| Korbelik et al. | Photodynamic therapy-mediated immune response against subcutaneous mouse tumors | |
| JP2019532080A5 (https=) | ||
| JP2019517504A5 (https=) | ||
| JP2022000060A5 (https=) | ||
| JPH08510993A (ja) | ホルモン補充方法 | |
| WO2017043633A1 (ja) | ＩＫＺＦ１変異を有するフィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 | |
| JP2014512391A5 (https=) | ||
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| Chen et al. | Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms | |
| EP1368061A4 (en) | FUSION CELLS AND CYTOKIN COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| WO2021150756A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
| CA2253064A1 (en) | Nef action inhibitor | |
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JP2023011549A5 (https=) | ||
| JPS63183528A (ja) | 悪性腫瘍治療剤 | |
| Liau et al. | Healing the unhealed wounds as the top priority to save cancer patients | |
| Zweiri et al. | Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-engineered tumour cells: a potential improvement for cancer therapeutics | |
| WO2025025480A1 (zh) | 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒 | |
| JP2005502690A5 (https=) | ||
| Traynor et al. | Hematopoietic stem cell transplantation for systemic lupus erythematosus | |
| Chassagne et al. | Progress report of a Phase II and a Phase III trial with etanidazole (SR-2508): A multicentre European study | |
| CLEASBY et al. | Modification of the Homograft Reaction in Corneal Transplantation: Further Studies | |
| JPWO2023004437A5 (https=) | ||
| WO2019084010A1 (en) | MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE |